Silo Pharma Enters Exclusive Global License for Alzheimer’s Therapeutic

July 16, 2024

DENVER, Colo., Jul 16, 2024 (247marketnews.com)- Silo Pharma, Inc. (Nasdaq:SILO) stated that it enhanced its intellectual property portfolio by securing an exclusive global license agreement to further develop, manufacture, and commercialize its Alzheimer’s drug SPC-14, for which Silo intends to utilize the FDA’s streamlined 505(b)(2) pathway for SPC-14 to shorten clinical timelines and reduce drug development costs.

Silo’s CEO, Eric Weisblum, commented, “In our view, our exclusive license for SPC-14 gives us the potential to meet a large unmet medical need. If approved, we believe SPC-14 could bring hope and relief for many families and patients. Early pre-clinical studies have shown stress reduction and cognitive improvement.”

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (SILO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.